ASP9801

AXP000102.1 · Oncolytic virus

Platform
vaccinia virus
Originator
Astellas Pharma
Sponsor
Astellas Pharma

Names

NameTypeSource
ASP9801preferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Replication
conditionally replicating
Modifications
thymidine kinase deleted (reported)
Transgenes
IL7, IL12A, IL12B
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C161021

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT03954067A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid TumorsCompletedPhase 12019-09-032024-04-1972Advanced Cancer; Metastatic Cancer; Solid Tumors

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41672594Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors.Journal for immunotherapy of cancer2026name in title: ASP9801

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 42922758Ex vivo human tumor slices more accurately predict patient responses to an oncolytic virus than in vivo mouse models.bioRxiv : the preprint server for biology2026name in abstract: ASP9801

Notes

Oncolytic vaccinia reported to carry IL-7 and IL-12; phase 1 intratumoral study with and without pembrolizumab completed April 2024 (NCT03954067). The transgene identities are from secondary sources and need checking.

How to cite

ASP9801 (AXP000102.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000102.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.